

Table S1. Minimization of immunosuppression (n=20 patients)

Recipient	Age	Donor BMI	Pre-Transplant anti-HLA Antibody	Minimization procedure	Minimization Timing	Post Transplant anti-HLA Antibody	Rejection	Rejection Histology
1	65	22	None	Tacrolimus withdrawal	M1	None	N	
2	33	26	Class I: A	Tacrolimus withdrawal	M8	class I: A	N	
3	53	23	None	Tacrolimus withdrawal	M7	None	N	
4	44	27.4	None	Ciclosporine withdrawal	M24	class I: B	N	
5	34	23.4	NA	mTor inhibitor since transplantation	M0	NA	N	
6	51	24.1	None	Switch Tacrolimus to mTor inhibitor	M4	class I/II: C, DR	N	
7	64	23.1	None	Tacrolimus withdrawal	M7	NA	N	
8	57	22.9	None	Switch Tacrolimus to mTor inhibitor, Mycophenolate Mofetil withdrawal	M12 M24	None	N	
9	61	30.5	None	Switch Tacrolimus to mTor inhibitor	M6	class I: B	N	
10	32	21.7	Class I/II: A, DR	Tacrolimus withdrawal	M9	class I/II: A, DR	N	
11	55	NA	None	Switch Ciclosporine to mTor inhibitor	M12	class II: DQ	N	
12	57	NA	None	Ciclosporine withdrawal Mycophenolate Mofetil withdrawal by the patient	NA	None	Y	NA
13	24	21.3	None	Ciclosporine withdrawal	M12	class II: DP	Y	TCMR
14	45	NA	None	Ciclosporine withdrawal, Mycophenolate Mofetil withdrawal by the patient	NA	NA	Y	NA
15	24	19.7	None	Tacrolimus withdrawal	M12	None	Y	TCMR
16	24	19	None	Tacrolimus withdrawal	M9	None	Y	Borderline
17	35	26.7	None	Non compliance to Tacrolimus and Mycophenolate Mofetil	NA	None	Y	TCMR
18	28	20.9	Class I: A	Tacrolimus withdrawal	M12	class I/II: A, DQ	Y	Mixed
19	59	23.7	None	Switch Tacrolimus to mTor inhibitor	M0.5	None	Y	TCMR
20	21	25.5	Class II: DR	Non compliance to Tacrolimus and Mycophenolate Mofetil	NA	None	Y	TCMR

NA: Not Available